今海国际(02225.HK)附属组合营 发展内窥镜产品相关业务
今海国际(02225.HK)公布,於1月7日,全资附属今海科技与刘镭及俞海波组合营今海医疗,注册资本为3,000万元人民币,拟通过生产、销售及分销(其中包括)4K、3D和荧光超高清内窥镜产品从事提供微创手术解决方案。
公司出资1,710万元,占57%,并将使用未动用所得款项净额出资。
董事会一直积极物色商机,以多元化现有业务及扩阔集团的收入基础,从而为公司股东带来更好回报。考虑到预期对优质医疗服务的需求将不断增长,尤其是在新型冠状病毒疫情期间,集团认为,成立合营公司为集团提供进入医疗解决方案行业的机会,以进一步扩大其客户基础及收入来源。
公司更改上市所得未动用所得款项净额,减少部分用於增购一间外籍工人宿舍拨资,至为上述公司注入注册资本。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.